Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Abbott Labs

Emergent BioSolutions

Inovio Pharmaceuticals

SIGA Technologies

Tonix Pharmaceuticals Hld

SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.

7 Monkeypox Stocks That May Take Off in Q2

Aethlon Medical

Geovax Labs

Monkeypox penny stocks to watch right now The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Watch As Monkeypox Cases Rise

DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 p.m. in New York City.

Chimerix to Present at Jefferies Global Healthcare Conference

Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.

7 Monkeypox Stocks to Watch Right Now

The monkeypox opportunity could already be baked into the prices of these stocks.

Are These 4 Stocks Smart Buys With the Monkeypox Outbreak?

The stock price of Chimerix Inc (NASDAQ: CMRX) increased by over 11% pre-market today. This is why.

Chimerix (CMRX) Stock: Why The Prise Rose Over 11% Today

Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.

3 Monkeypox Stocks That Soared Last Week

Immix Biopharma

TherapeuticsMD

Are these biotech penny stocks on your watchlist right now? The post Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?

6 Stocks To Watch Amid Monkeypox Outbreak

Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.

Monkeypox Fears Drive Smallpox Antiviral Makers Higher

DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright Global Investment Conference made available on Tuesday, May 24, 2022 at 7:00 a.m. ET.

Chimerix to Present at H.C. Wainwright Global Investment Conference

The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.

Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Mike Sherman – President & Chief Executive Officer Michael Andriole – Chief Financial & Business Officer Allen Melemed – Chief Medical Officer Joshua Allen – Chief Technology Officer, Imipridones Michelle Laspaluto – Vice President, Strategic Planning & Investor Relations Conference Call Participants Maury Raycroft – Jefferies Edward White – H.C. Wainwright & Co. Naureen Quibria – Maxim Group Soumit Roy – Jones Trading David Nierengarten – Wedbush Securities Troy Langford – Cowen Inc. Operator Good morning, ladies, and gentlemen, and welcome to the Chimerix First Quarter 2022 Earnings Conference Call.

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q1 2022 Results - Earnings Call Transcript

Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program.

Here's Why Chimerix Stock Is Imploding Today

Chimerix (CMRX) stock is falling hard on Monday following the release of its earnings report for the first quarter of 2022. The post Chimerix (CMRX) Stock Plummets 60% After Q1 Earnings Disappointment appeared first on InvestorPlace.

Chimerix (CMRX) Stock Plummets 60% After Q1 Earnings Disappointment

Emergent BioSolutions Inc (NYSE: EBS) has agreed to acquire Chimerix Inc's (NASDAQ: CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox.  "It exemplifies our thoughtful M&A strategy as.

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions –

Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update

Shares of Chimerix Inc. CMRX, +3.41% shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to $337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open.

Chimerix stock surges after deal to sell smallpox treatment Tembexa for up to $337.5 million, plus royalties

– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics –

Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Josh Allen, Ph.D., Chief Technology Officer of Imipridones, will participate in a panel discussion hosted by Maxim Group. The event, “Exploring New Targets for Pediatric Brain Cancer,” will take place on Thursday, May 19, 2022 at 9:00 a.m. ET.

Chimerix to Participate in Maxim Group Panel Discussion

DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference taking place March 28-30, 2022.

Chimerix to Present at Maxim Group 2022 Virtual Growth Conference

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2021 Results - Earnings Call Transcript

Chimerix (CMRX) delivered earnings and revenue surprises of -309.09% and 99.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q4 Loss, Lags Revenue Estimates

– TEMBEXA RFP Response Submitted and Under Review with BARDA –

Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

News for Chimerix Stock (CMRX)